

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09402820
Filing Date	1999-10-12
First Named Inventor	Benjamin Chain
Art Unit	1645
Examiner Name	P. A. Duffy
Attorney Docket Number	20555/1203301-US1

U.S. PATENTS[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)**U.S. PATENT APPLICATION PUBLICATIONS**[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)**FOREIGN PATENT DOCUMENTS**[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

[Add](#)**NON-PATENT LITERATURE DOCUMENTS**[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09402820
Filing Date	1999-10-12
First Named Inventor	Benjamin Chain
Art Unit	1645
Examiner Name	P. A. Duffy
Attorney Docket Number	20555/1203301-US1

/P.D./	1	BACSKAI, B.J. et al. "Imaging of Amyloid-Beta Deposits in Brains of Living Mice Permits Direct Observation of Clearance of Plaques With Immunotherapy." Nature Medicine, March 2001, Vol. 7, No. 3, pp. 369-372	<input type="checkbox"/>
/P.D./	2	FRENKEL, Dan et al. "Modulation of Alzheimer's Beta-Amyloid Neurotoxicity by Site-Directed Single Chain Antibody." Journal of Neuroimmunology, Vo. 160, No. 1-2, July 2000, pp. 23 - 31	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Patricia Duffy/	Date Considered	06/09/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/402,820-Conf. #6495	
			Filing Date	October 12, 1999	
			First Named Inventor	Benjamin Chain	
			Art Unit	1645	
			Examiner Name	P. A. Duffy	
Sheet	1	of	1	Attorney Docket Number	20555/1203301-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/P.D.	AA*	US-6,787,637	09-07-2004	Schenk	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁴
/P.D./	CA	Bard F et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. <i>Nature Medicine</i> , 6(8): 916-919, 2000.		
/P.D./	CB	Saldo T et al. Amino-and carboxyl-terminal heterogeneity of beta-amyloid peptides in human brain. <i>Neurosci Lett</i> , 215: 173-176, 1996.		
/P.D./	CC	Harigaya Y et al. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. <i>Biochem Biophys Res Comm</i> . 276: 422-427, 2000.		
/P.D./	CD	Frenkel D et al. N-terminal EFRH sequence of Alzheimer's b-amyloid peptide represents the epitope of its anti-aggregating antibodies. <i>J Neuroimmunol</i> , 88: 85-90, 1998.		
/P.D./	CE	Su Y and Ni B. Selective deposition of amyloid-beta protein in the entorhinal-dentate projection of a transgenic mouse model of Alzheimer's disease. <i>J. Neurosci Res</i> , 53: 177-186, 1998.		
/P.D./	CF	Buxbaum JN. Treatment and prevention of the amyloidoses: Can the lessons learned by applied to sporadic inclusion-body myositis? 66(Supp 1): S110-S113, 2006.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Patricia Duffy/	Date Considered	06/09/2007
-----------------------	------------------	--------------------	------------